← Leaderboards
Paul D Crowe
Orphagen Pharmaceuticals
$2,256,911
Attributed
$2,256,911
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2011–20$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,256,911 · 3
By mechanism
R44$1,812,843 · 1
R43$444,068 · 2
Top collaborators
No co-investigators on record.
Most similar at Orphagen Pharmaceuticals
Same institution · by research overlap
- Scott McNear Thacher$9,190,724
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculePharmacologyAffectBaseSpecificitySafetyPharmaceutical PreparationsPropertyProductionAndrogensToxicologyCostDoseTestosteronePharmacological TreatmentInfertilityLeadBiological AvailabilityBioavailableGenerationsOralRattusAnimalsEndometrial
Grant awards (4)
Translational feasibility of an oral, non-hormonal, male contraceptive pill$719,059
R44 · FY2020 · HD · contact PI
Translational feasibility of an oral, non-hormonal, male contraceptive pill$1,093,784
R44 · FY2019 · HD · contact PI
Small Molecule Target for Inhibition of Cortisol in Cushing's Syndrome$223,229
R43 · FY2014 · DK · contact PI
A Novel Target for the Treatment of Endometriosis$220,839
R43 · FY2011 · HD · contact PI